Cannabis Use and Potential Interference with Antidepressant Medications

Cannabis Use and Potential Interference with Antidepressant Medications

‍

Cannabis use has become increasingly common among people who also take prescription antidepressants. This overlap is clinically important because cannabinoids, especially cannabidiol (CBD), may alter the metabolism of certainantidepressant medications and increase the likelihood of adverse effects.Recent peer-reviewed research suggests that the most supported concern is notthat cannabis universally reduces antidepressant effectiveness, but thatcannabis-derived compounds can interfere with drug metabolism and affectmedication exposure (Qian et al., 2019; Vaughn et al., 2021).

Many antidepressants are metabolized through hepatic cytochrome P450 enzymepathways. Cannabis products, particularly those containing CBD, may inhibitsome of these enzymes and thereby increase serum concentrations of certainantidepressants (Qian et al., 2019). This interaction is especially relevantfor selective serotonin reuptake inhibitors (SSRIs), including citalopram,escitalopram, and sertraline (Vaughn et al., 2021). As a result, concurrentcannabis use may increase the risk of dose-related adverse effects even whenthe prescribed antidepressant dose has not changed.

Although tetrahydrocannabinol (THC) is often the most publicly recognizedcomponent of cannabis, CBD appears to be the more significant concern inantidepressant drug interactions. Anderson et al. (2021) examined theinteraction between CBD and citalopram or escitalopram and found evidence fromboth in vitro and in vivo analyses that CBD inhibited the metabolism of thesemedications. The study also reported increased plasma concentrations ofcitalopram in patients receiving CBD concurrently, suggesting that thisinteraction may be clinically meaningful.

Elevated antidepressant concentrations may contribute to a greater risk ofadverse effects such as dizziness, fatigue, sedation, gastrointestinaldisturbance, and cognitive impairment (Vaughn et al., 2021). In clinicalsettings, this may present as a patient feeling more sedated, mentally foggy,or physically unwell after beginning cannabis or CBD use. These effects may bemistaken for worsening psychiatric symptoms unless clinicians specificallyassess cannabinoid exposure.

The clearest recent evidence involves citalopram and escitalopram becausethese medications have direct pharmacokinetic data demonstrating interactionwith CBD (Anderson et al., 2021). Sertraline has also been identified as apotential interaction concern, based on pharmacologic modeling and clinicalconsiderations described in recent literature (Vaughn et al., 2021). Fluoxetinehas been implicated in case-based evidence as well. In one case report,Anderson et al. (2022) described a possible drug-gene-drug interactioninvolving CBD, CYP2D6*4, and fluoxetine, suggesting that individual metabolicvulnerability may further increase the risk of adverse outcomes.

Case reports do not establish prevalence, but they do provide clinicallyrelevant evidence that these interactions can occur in real patients. For thatreason, the available evidence supports caution rather than alarm. Currentresearch does not support the conclusion that all cannabis use is incompatiblewith all antidepressants. However, it does support the conclusion that cannabisproducts, especially those containing CBD, may interfere with the metabolism ofsome antidepressants and increase the likelihood of adverse effects (Qian etal., 2019; Vaughn et al., 2021).

In summary, the most evidence-based conclusion from the recent literature isthat cannabis use may interfere with certain antidepressant medications throughpharmacokinetic mechanisms. The strongest support exists for interactionsinvolving CBD and SSRIs such as citalopram, escitalopram, and sertraline, withadditional case-based evidence involving fluoxetine (Anderson et al., 2021;Anderson et al., 2022; Vaughn et al., 2021). Because these interactions mayaffect medication safety and tolerability, patients taking antidepressant sshould disclose cannabis and CBD use to their prescribing clinician.

References

Anderson, L. L., Arnold, J. C., McGregor, I. S., & Nation, T. R. (2022).A potential drug-gene-

drug interaction between cannabidiol, CYP2D6*4, andfluoxetine: A case report. Journal

of Clinical Psychopharmacology, 42(4),422–424.

https://doi.org/10.1097/JCP.0000000000001568

‍

Anderson, L. L., Doohan, P. T., Oldfield, L. D., Kevin, R. C., Arnold, J.C., Nation, T., &

McGregor, I. S. (2021). Citalopram and cannabidiol:In vitro and in vivo evidence of

pharmacokinetic interactions relevant to thetreatment of anxiety disorders in young

people. Journal of Clinical Psychopharmacology,41(5), 525–533.

https://doi.org/10.1097/JCP.0000000000001427

‍

Qian, Y., Gurley, B. J., & Markowitz, J. S. (2019). The potential forpharmacokinetic

interactions between cannabis products andconventional medications. Journal of Clinical

Psychopharmacology, 39(5), 462–471.https://doi.org/10.1097/JCP.0000000000001089

‍

Vaughn, S. E., Strawn, J. R., Poweleit, E. A., Sarangdhar, M., & Ramsey,L. B. (2021). The

impact of marijuana on antidepressant treatment inadolescents: Clinical and

pharmacologic considerations. Journal ofPersonalized Medicine, 11(7), Article 615.

https://doi.org/10.3390/jpm11070615

‍